Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders

Details for Australian Patent Application No. 2007213833 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Mattei, Patrizio; Conte, Aurelia; Mueller, Werner; Maugeais, Cyrille; Kuehne, Holger; Luebbers, Thomas; Pflieger, Philippe

Agent Spruson & Ferguson

Pub. Number AU-A-2007213833

PCT Pub. Number WO2007/090750

Priority 06101377.7 07.02.06 EP

Filing date 29 January 2007

Wipo publication date 16 August 2007

International Classifications

A61K 31/695 (2006.01) - Silicon compounds

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

C07F 7/08 (2006.01) Compounds containing elements of the 4th Group of the Periodic System

Event Publications

28 August 2008 PCT application entered the National Phase

  PCT publication WO2007/090750 Priority application(s): WO2007/090750

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007213834-Heterobicyclic amide derivatives

2007213832-Benzamide and heteroarene derivatives as CETP inhibitors